興旺發丫

    • 興旺發丫興旺發丫
      ·2023-02-14
      QC. I vaG imh @TigerStars I.  B🚉

      Palantir: Soaring On Good News

      SummaryPalantir Technologies Inc. reported Q4 results that beat estimates on both lines.The company
      Palantir: Soaring On Good News
      164Comment
      Report
    • 興旺發丫興旺發丫
      ·2022-10-06
      👍

      Broadcom Inc., (AVGO:NASDAQ): Daily Chart, September 28 2022,

      @TradingLounge
      Broadcom Inc., Elliott Wave Technical Analysis Broadcom Inc., (AVGO:NASDAQ): Daily Chart, September 28 2022, AVGO Stock Market Analysis: I wanted to zoom out to show you how we are approaching thevolume point of control off the entire rally from the Covid-19 lows. AVGO Elliott Wave count: Z of (2). AVGO Trading Strategy: Looking for a clear sign of upside resumption to then place long termtrades. AVGO Technical Indicators:We have been in oversold territory for a while now that is couldbecome interesting to buy in the future. TradingLounge Analyst: Alessio Barretta Source Tradinglounge.com Get trial here! Broadcom Inc., AVGO: 4-hour Chart, September 28 2022 Broadcom Inc., Elliott Wave Technical Analysis AVGO Stock Market Analysis: I would be looking for further downside as the m
      Broadcom Inc., (AVGO:NASDAQ): Daily Chart, September 28 2022,
      5801
      Report
    • 興旺發丫興旺發丫
      ·2022-04-25
      👍

      Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play

      @Smartkarma Research Network
      Tigermed’s high growth and high valuation are inseparable from continuous M&As and investment. However, uncertain macro environment and risk of recession question if "CRO+PE/VC" model is a safe play. Despite solid growth in 2021, if seen from prior years, the revenue YoY growth rate and net profit YoY growth rate showed a state of divergence, which is “interesting”. Since half of Tigermed’s net profits were from investment income,it’s not logical to apply the valuation methods of traditional CXO to Tigermed. Its CRO and investment should be valued separately. The poor IPO sentiment, risk of recession and the domestic healthcare rational return would make investors reconsider if Tigermed’s “CRO + PE/VC business model” would be a safe play. By Xinyao (Criss) Wang - http
      Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play
      499Comment
      Report
    • 興旺發丫興旺發丫
      ·2022-03-18
      👍

      Pfizer Shares Rose More Than 2% in Morning Trading

      Pfizer shares rose more than 2% in morning trading.Thirty five generic drugmakers around the world w
      Pfizer Shares Rose More Than 2% in Morning Trading
      759Comment
      Report
    • 興旺發丫興旺發丫
      ·2022-02-23
      👍
      Sorry, this post has been deleted
      531Comment
      Report
    • 興旺發丫興旺發丫
      ·2021-12-26
      Like 

      Can This Top Blue Chip Stock Handle Soaring Inflation?

      We are in strange times right now, so how companies navigate the current environment is vital to their success.
      Can This Top Blue Chip Stock Handle Soaring Inflation?
      476Comment
      Report
       
       
       
       

      Most Discussed

       
       
       
       
       

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial